雷珠单抗治疗不同疾病所致黄斑水肿的疗效观察

发布时间：2018-01-14 05:20

本文关键词：雷珠单抗治疗不同疾病所致黄斑水肿的疗效观察　出处：《国际眼科杂志》2016年12期 　论文类型：期刊论文

【摘要】：目的:探讨玻璃体腔注射雷珠单抗治疗因糖尿病、视网膜静脉阻塞继发黄斑水肿的安全及有效性。方法:选取2013-06/2016-02在北京航天中心医院眼科因糖尿病继发黄斑水肿(DME)和视网膜静脉阻塞继发黄斑水肿(RVO-ME)收治入院,并符合本研究纳入及排除标准的患者35例38眼,其中DME 23眼,RVO-ME 15眼。患眼接受玻璃体腔雷珠单抗(0.5mg/0.05m L)注射治疗,治疗前和治疗后1、3d,1wk、1mo定期门诊回访观察最佳矫正视力(BCVA)、黄斑中心凹厚度(CRT)、眼压。比较雷珠单抗治疗DME及RVO-ME前后的疗效。结果:DME组及RVO-ME组治疗后1、3d,1wk的BCVA均较治疗前提高,差异均有统计学意义(P0.05),而两组1mo的BCVA与治疗前相比差异均无统计学意义(P0.05)。DME组及RVO-ME组治疗后1、3d,1wk,1mo的CRT均较治疗前明显改善,差异均有统计学意义(P0.05)。在BCVA及CRT方面比较,雷珠单抗对于RVOME及DME疗效差异无统计学意义(P0.05)。结论:玻璃体腔注射雷珠单抗对DME及RVO-ME的治疗均安全有效。
[Abstract]:Objective: to investigate the treatment of diabetes mellitus by intravitreal injection of Lei Zhu McAb. Safety and efficacy of macular edema secondary to retinal vein occlusion methods: DMEs were selected from Beijing Aerospace Center Hospital in 2013-06 / 2016-02 for diabetic secondary macular edema. And retinal vein occlusion secondary macular edema (RVO-MEA). 35 patients (38 eyes), including 23 eyes of DME, met the criteria of inclusion and exclusion in this study. 15 eyes of RVO-ME were treated by injection of 0.5 mg / 0.05m L of vitreous vitreous vitreous monoclonal antibody, 1 day before and 1 day after treatment for 1 wk. The best corrected visual acuity (BCVA) and macular foveal thickness (CRT) were observed regularly at 1 month. Intraocular pressure (IOP). The therapeutic effects of Lei Zhu McAb on DME and RVO-ME were compared before and after treatment. Results the BCVA of 1: DME group and RVO-ME group were significantly higher than that of before and after treatment at 1: 3 d and 1 wk after treatment. The difference was statistically significant (P 0.05), but there was no significant difference in BCVA between the two groups after 1 month compared with that before treatment. There was no significant difference between the two groups in P0.05 + DME group and RVO-ME group after 1 month treatment. The CRT of 3 days and 1 week after treatment was significantly improved compared with that before treatment, and the difference was statistically significant (P 0.05). The BCVA and CRT were compared. There was no significant difference in the efficacy of Lei Zhu McAb in the treatment of RVOME and DME. Conclusion: injection of Lei Zhu McAb into vitreous cavity is safe and effective in the treatment of both DME and RVO-ME.
【作者单位】：锦州医科大学研究生学院;航天中心医院眼科;
【基金】：中国航天科工集团公司2014年医疗卫生科研项目(No.2014-LCYL-006)~~
【分类号】：R774.5
【正文快照】： 0引言各种疾病所致的黄斑水肿(macular edema,ME)是引起视力下降的重要原因,糖尿病视网膜病变(DR)、视网膜静脉阻塞(RVO)是最常见的引起黄斑水肿,造成患者视力下降的疾病,随着抗血管内皮生长因子(VEGF)的研发及应用,其在黄斑水肿治疗上的成就逐步得到人们的认可。2012年初,

【相似文献】